Zobrazeno 61 - 70
of 1 642
pro vyhledávání: ''
Publikováno v:
Oncology. 100(3)
Background: Platinum + fluoropyrimidine is a standard front-line therapy for unresectable gastroesophageal adenocarcinoma (GA). Subsequent therapy recommendations are ramucirumab + paclitaxel (RAM/PAC), taxane, irinotecan, or trifluridine-tipiracil.
Autor:
Angeline Ginzac, Ioana Molnar, Xavier Durando, Pierre-François Montoriol, Cécile Mione, Hakim Mahammedi, Tressie Herrmann
Publikováno v:
Oncology
Oncology, Karger, 2022, ⟨10.1159/000520833⟩
Oncology, Karger, 2022, ⟨10.1159/000520833⟩
Introduction: The advent of immune checkpoint inhibitors (ICIs) such as nivolumab has enabled outcomes for metastatic renal cell carcinoma (mRCC) to be improved. However, only around 25% of patients respond to these therapies without being able to fo
Autor:
Akira Sawaki, Teiji Kuzuya, Ryoji Miyahara, Atsushi Sugioka, Arisa Mii, Takuji Nakano, Yoshiki Hirooka, Naoto Kawabe, Kazunori Nakaoka, Yohei Miyachi, Hiroyuki Tanaka, Sayaka Kamejima, Takeshi Takahara, Yutaro Kato, Senju Hashimoto
Publikováno v:
Oncology. 100(1)
Introduction: The aim of this study was to investigate the early changes in alpha-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) levels in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab and to
Autor:
Vivek Subbiah, Roman Groisberg
Publikováno v:
Oncology
Perivascular epithelioid cell tumor (PEComa) is a rare mesenchymal soft tissue neoplasm often linked to mTOR pathway activation via TSC2 mutation. We analyzed a series of 31 consecutive metastatic PEComa (mPEComa) cases using a combined DNA/RNA hybri
Autor:
Chih-Hung Hsu, Chen Yuan Lin, Ming-Yu Lien, Li-Chun Lu, Jhe-Cyuan Guo, Chia-Chi Lin, Ta-Chen Huang, Hung-Yang Kuo
Publikováno v:
Oncology. 99(10)
Introduction: Heterogeneous tumor response has been reported in cancer patients treated with immune checkpoint inhibitors (ICIs). This study investigated whether the tumor site is associated with the response to ICIs in patients with recurrent or met
Publikováno v:
Oncology. 99(11)
Introduction: Tumor and systemic inflammatory markers predict survival. This retrospective study aimed to explore the changes in CRP, CA19-9, and other routine laboratory tests during preoperative oncological therapy as prognostic factors in pancreat
Autor:
Satoshi Nozaki, Ryosuke Ando, Yusuke Noda, Yosuke Sugiyama, Taku Naiki, Toshiki Etani, Takashi Nagai, Teruki Isobe, Daisuke Matsumoto, Takahiro Yasui, Nobuhiko Shimizu, Noriyasu Kawai, Keitaro Iida, Hiroki Kubota, Shuzo Hamamoto
Publikováno v:
Oncology. 99(10)
Objectives: The aim of the study was to examine the effectiveness of a modified-short hydration gemcitabine and cisplatin (m-shGC) regimen for patients with metastatic urothelial carcinoma (mUC) and to assess the efficacy of a geriatric nutritional r
Autor:
Paolo Aretini, Alessandra Perutelli, Ludovico Muzii, Pietro Bottone, Lavinia Domenici, Pierluigi Benedetti Panici, Alessandro Tonacci, Silvia Garibaldi
Publikováno v:
Oncology. 99(9)
Introduction: Increasing evidence demonstrates a crucial role of inflammation in inducing and promoting several cancers. Pro-inflammatory upregulation of cytokines such as IL-6 has been implicated in cervical cancer development and progression throug
Autor:
Akihiko Sano, Yuki Shimoda, Hiroshi Saeki, Makoto Sakai, Keigo Hara, Makoto Sohda, Kengo Kuriyama, Nobuhiro Nakazawa, Munenori Ide, Ken Shirabe, Yasunari Ubukata, Tetsunari Oyama, Hiroomi Ogawa, Takehiko Yokobori
Publikováno v:
Oncology. 99(11)
Introduction: We investigated whether the expression of L-type amino acid transporter 1 (LAT-1) in clinical gastric cancer (GC) patients could predict patient therapeutic response to postoperative adjuvant chemotherapy. Methods: Immunohistochemistry
Autor:
Hiroshi Kagamu, Atsuto Mouri, Kenya Kanazawa, Kunihiko Kobayashi, Yutaka Yamada, Tatsuya Ibe, Yoichiro Hamamoto, Hisao Imai, Ou Yamaguchi, Hiroyuki Minemura, Takayuki Kaburagi, Keita Mori, Takayuki Kishikawa, Koichi Minato, Kyoichi Kaira, Takashi Kasai
Publikováno v:
Oncology. 99(9)
Background: Among patients with non-small cell lung cancer (NSCLC), the impact of first-line treatment on overall survival (OS) may be influenced by subsequent therapies. Thus, using patient-level data, we assessed the relationships of progression-fr